Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

Core Insights - Oragenics, Inc. is preparing for its Phase 2a clinical trial of ONP-002, a concussion treatment, and is participating in the SCOPE Summit 2026 to engage with global clinical research leaders [1][2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [4] - The lead candidate, ONP-002, aims to address significant unmet medical needs in concussion and mild traumatic brain injury, with clinical trials planned in Australia and subsequent trials in the U.S. [4] Industry Engagement - The SCOPE Summit 2026 will host over 1,200 companies from 30 countries, covering topics such as trial planning, operations, and innovation in clinical research [3] - The event is seen as a critical opportunity for Oragenics to connect with experts in biopharma, scientific research, and regulatory affairs [2]